These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 594391)

  • 1. Thromboxane synthetase inhibitors as pharmacological tools: differential biochemical and biological effects on platelet suspensions.
    Needleman P; Bryan B; Wyche A; Bronson SD; Eakins K; Ferrendelli JA; Minkes M
    Prostaglandins; 1977 Nov; 14(5):897-907. PubMed ID: 594391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of imidazole and 9,11-azoprosta-5,13-dienoic acid. Two selective thromboxane synthetase inhibitors.
    Fitzpatrick FA; Gorman RR
    Biochim Biophys Acta; 1978 Mar; 539(2):162-72. PubMed ID: 629996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A selective thromboxane synthetase inhibitor blocks the cAMP lowering activity of PGH2.
    Gorman RR; Fitzpatrick FA; Miller OV
    Biochem Biophys Res Commun; 1977 Nov; 79(1):305-13. PubMed ID: 200243
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of human platelet thromboxane synthetase by 9,11-azoprosta-5,13-dienoic acid.
    Gorman RR; Bundy GL; Peterson DC; Sun FF; Miller OV; Fitzpatrick FA
    Proc Natl Acad Sci U S A; 1977 Sep; 74(9):4007-11. PubMed ID: 269449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
    Bertele V; De Gaetano G
    Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of thromboxane A2 biosynthesis in human platelets by burimamide.
    Allan G; Eakins KE; Kulkarni PS; Levi R
    Br J Pharmacol; 1980; 71(1):157-64. PubMed ID: 6781572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic inhibition of thromboxane synthetase and platelet aggregation: modulatory role of cyclooxygenase products.
    Bertelé V; Falanga A; Tomasiak M; Chiabrando C; Cerletti C; de Gaetano G
    Blood; 1984 Jun; 63(6):1460-6. PubMed ID: 6426554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lag-phase of arachidonic acid-induced secretion in responders and non-responders to the thromboxane-synthetase inhibitors: involvement of cyclic-AMP.
    Lecompte T; Joussemet M; Hainaut J
    Thromb Res; 1984 Jul; 35(1):91-7. PubMed ID: 6089368
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostaglandins and human platelet aggregation. Implications for the anti-aggregating activity of thromboxane-synthase inhibitors.
    Rajtar G; Cerletti C; Castagnoli MN; Bertelé V; de Gaetano G
    Biochem Pharmacol; 1985 Feb; 34(3):307-10. PubMed ID: 3918536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of platelet aggregation by 1-alkylimidazole derivatives, thromboxane A synthetase inhibitors.
    Kayama N; Sakaguchi K; Kaneko S; Kubota T; Fukuzawa T; Kawamura S; Yoshimoto T; Yamamoto S
    Prostaglandins; 1981 Apr; 21(4):543-54. PubMed ID: 7196056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of imidazole as a selective inhibitor thromboxane synthetase in human platelets.
    Needleman P; Raz A; Ferrendelli JA; Minkes M
    Proc Natl Acad Sci U S A; 1977 Apr; 74(4):1716-20. PubMed ID: 193113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of thromboxane synthetase inhibition on arachidonate metabolism and platelet behaviour.
    Parry MJ
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):23S-29S. PubMed ID: 6401997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical and pharmacological evaluation of thromboxane synthetase inhibitors.
    Gorman RR
    Adv Prostaglandin Thromboxane Res; 1980; 6():417-25. PubMed ID: 6247892
    [No Abstract]   [Full Text] [Related]  

  • 14. Studies on the thromboxane synthesizing system in human platelet microsomes.
    Tai HH; Yuan B
    Biochim Biophys Acta; 1978 Dec; 531(3):286-94. PubMed ID: 737191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of thromboxane synthetase inhibitors on platelet function: enhancement by inhibition of phosphodiesterase.
    Smith JB
    Thromb Res; 1982 Nov; 28(4):477-85. PubMed ID: 6891843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of 9,11-azo-13-oxa-15-hydroxyprostanoic acid, a potent inhibitor of platelet aggregation.
    Kam ST; Portoghese PS; Gerrard JM; Dunham EW
    J Med Chem; 1979 Nov; 22(11):1402-8. PubMed ID: 533888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet thromboxane synthetase inhibitors with low doses of aspirin: possible resolution of the "aspirin dilemma".
    Bertelé V; Falanga A; Tomasiak M; Dejana E; Cerletti C; de Gaetano G
    Science; 1983 Apr; 220(4596):517-9. PubMed ID: 6682245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Synthesis of thromboxane A2: limiting stages of primary thrombocyte aggregation in humans initiated by arachidonic acid and its metabolic products].
    Mevkh AT; Basevich VV; Varfolomeev SD
    Biokhimiia; 1984 Dec; 49(12):2035-40. PubMed ID: 6441604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competitive antagonism at thromboxane receptors in human platelets.
    Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
    Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet rich plasma transforms exogenous prostaglandin endoperoxide H2 into thromboxane A2.
    Fitzpatrick FA; Gorman RR
    Prostaglandins; 1977 Nov; 14(5):881-9. PubMed ID: 594390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.